Literature DB >> 28770796

Antiarrhythmic Drugs: Age, Race, and Gender Effects.

Deborah Wolbrette1.   

Abstract

Women have a higher risk of developing torsade de pointes when taking QT-prolonging antiarrhythmic drugs. Elderly women with heart failure may have the highest risk of proarrhythmia. Greater caution should be used when treating women with these drugs, especially when additional risk factors for developing proarrhythmia are present. Women with congenital heart disease frequently experience arrhythmias during pregnancy, and use of antiarrhythmic drugs in this setting poses a special challenge. In the elderly population, the risk of antiarrhythmic drug use may outweigh the benefit, especially in individuals with asymptomatic arrhythmias. Limited data suggest potential ethnic differences in arrhythmic substrates and in proarrhythmic response to antiarrhythmic drugs.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Year:  2010        PMID: 28770796     DOI: 10.1016/j.ccep.2010.06.007

Source DB:  PubMed          Journal:  Card Electrophysiol Clin        ISSN: 1877-9182


  3 in total

1.  Race and Socioeconomic Status Regulate Lifetime Risk of Atrial Fibrillation.

Authors:  Mark D McCauley; Dawood Darbar
Journal:  Circ Arrhythm Electrophysiol       Date:  2018-07

2.  Representation of women, older patients, ethnic, and racial minorities in trials of atrial fibrillation.

Authors:  Muhammad Zia Khan; Muhammad Bilal Munir; Safi U Khan; Charumathi Raghu Subramanian; Muhammad Usman Khan; Zain Ul Abideen Asad; Swapna Talluri; Aarthi Madhanakumar; Ahmad Naeem Lone; Muhammad Shahzeb Khan; Erin D Michos; Mohamad Alkhouli
Journal:  Pacing Clin Electrophysiol       Date:  2021-02-03       Impact factor: 1.976

3.  Influence of heart rate correction formulas on QTc interval stability.

Authors:  Irena Andršová; Katerina Hnatkova; Martina Šišáková; Ondřej Toman; Peter Smetana; Katharina M Huster; Petra Barthel; Tomáš Novotný; Georg Schmidt; Marek Malik
Journal:  Sci Rep       Date:  2021-07-12       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.